Work

De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute

Year: 2016

Type: article

Source: Cancer Immunology Research

DOI: 10.1158/2326-6066.cir-16-0045

Authors: Ira Mellman, Vanessa M. Hubbard-Lucey, Matthew J. Tontonoz, Michael D. Kalos, Daniel S. Chen, James P. Allison, Charles G. Drake, Hy Levitsky, Nils Lonberg, Sjoerd H. van der Burg, Douglas T. Fearon, E. John Wherry, Israel Lowy, Robert H. Vonderheide, Patrick Hwu

Institutions: Genentech, Cancer Research Institute, The University of Texas MD Anderson Cancer Center, Johns Hopkins University, Johns Hopkins Medicine, Roche (Switzerland), Bristol-Myers Squibb (United States), Leiden University Medical Center, Cold Spring Harbor Laboratory, University of Pennsylvania, Regeneron (United States)

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2325614117

FWCI: 3.099

Cites: 72

Cited by: 31

Related to: 10